Purpose: Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors,
have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; …

Melanoma is the most dangerous form of skin cancer, with a steeply rising incidence and a
poor prognosis in its advanced stages. Melanoma is highly resistant to traditional …

Background Vemurafenib, a novel selective small molecule inhibitor of BRAF, has recently
been shown to be effective in the treatment of melanomas harboring the BRAF V600E …

While multiple mechanisms of BRAFV600-mutant melanoma resistance to targeted MAPK
signaling inhibitors (MAPKi) have been reported, the epigenetic regulation of this process …

Advanced differentiated thyroid cancer (DTC), defined by clinical characteristics including
gross extrathyroidal invasion, distant metastases, radioiodine (RAI) resistance, and avidity …

Malignant melanoma is the most deadly form of skin cancer. It originates from melanocytic
cells and can also arise at other body sites. Early diagnosis and appropriate medical care …

Elevated activity of the mitogen-activated protein kinase (MAPK) signaling cascade is found
in the majority of human melanomas and is known to regulate proliferation, survival and …

Aberrant activation of the BRAF kinase occurs in∼ 60% of melanomas, and although BRAF
inhibitors have shown significant early clinical success, acquired resistance occurs in most …

Abstract BRAF V600E is the most common mutation in cutaneous melanoma and has
become the target of treatment for patients with metastatic melanoma. A number of methods …

Background Metastatic melanoma is an aggressive form of skin cancer with a high mortality
rate and the fastest growing global incidence rate of all malignancies. The introduction of …